Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00243074 · OUTCOME

Adverse Events

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery · Source last updated 2018-01-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Participants
Interval / dispersion
Not reported
Time frame
Patients were assessed for adverse events every day for as long as they remained on protocol treatment, up to 5 years.

What was measured

Only adverse events that are possibly, probably or definitely related to study drug are reported.

Analysis population: Eligible patients who received any amount of protocol treatment with AZD2171 (cediranib maleate)

Groups in this outcome

AZD2171 (Cediranib Maleate)

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD2171 (Cediranib Maleate)47

Reported measurements

Anorexia
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)3Not reportedNot reportedNot reportedNot reported
Apnea
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Ataxia (incoordination)
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Cognitive disturbance
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Colitis
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Confusion
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)2Not reportedNot reportedNot reportedNot reported
Constipation
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Dehydration
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)3Not reportedNot reportedNot reportedNot reported
Diarrhea
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)4Not reportedNot reportedNot reportedNot reported
Dizziness
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Encephalopathy
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Fatigue (asthenia, lethargy, malaise)
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)7Not reportedNot reportedNot reportedNot reported
Hypertension
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)15Not reportedNot reportedNot reportedNot reported
Hypotension
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Inf (clin/microbio) w/Gr 3-4 neuts - Blood
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Memory impairment
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Metabolic/Laboratory-Other (Specify)
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Muscle weakness, not d/t neuropathy - body/general
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Nausea
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)2Not reportedNot reportedNot reportedNot reported
Necrosis, GI - Esophagus
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Neuropathy: sensory
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Pain - Chest wall
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Pain - Head/headache
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Pain - Intestine
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Pain - Pain NOS
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Pain - Tumor pain
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Perforation, GI - Ileum
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Potassium, serum-low (hypokalemia)
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Proteinuria
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)2Not reportedNot reportedNot reportedNot reported
Rash: hand-foot skin reaction
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)2Not reportedNot reportedNot reportedNot reported
Renal failure
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)2Not reportedNot reportedNot reportedNot reported
Sodium, serum-low (hyponatremia)
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Speech impairment (e.g., dysphasia or aphasia)
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Thrombosis/thrombus/embolism
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)3Not reportedNot reportedNot reportedNot reported
Vomiting
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)1Not reportedNot reportedNot reportedNot reported
Weight loss
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Anorexia
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Apnea
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Ataxia (incoordination)
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Cognitive disturbance
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Colitis
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Confusion
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Constipation
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Dehydration
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    Diarrhea
  10. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Dizziness
  11. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Encephalopathy
  12. categories
    1. measurements
      1. group Id
        OG000
        value
        7
    title
    Fatigue (asthenia, lethargy, malaise)
denoms
  1. counts
    1. group Id
      OG000
      value
      47
    units
    Participants
description
Only adverse events that are possibly, probably or definitely related to study drug are reported.
groups
  1. id
    OG000
    title
    AZD2171 (Cediranib Maleate)
param Type
NUMBER
population Description
Eligible patients who received any amount of protocol treatment with AZD2171 (cediranib maleate)
reporting Status
POSTED
time Frame
Patients were assessed for adverse events every day for as long as they remained on protocol treatment, up to 5 years.
title
Adverse Events
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice